Advisers to Glaxo Wellcome and SmithKline Beecham can relax in the knowledge they will receive their fees, as the US Federal Trade Commission agrees to clear the $68bn (€77.5bn) pharmaceuticals merger.
The Federal Trade Commission clearance marks the final regulatory hurdle to the merger, which is due to complete on December 27.